Researcher:
Bayraktutar, Betül

Profile Picture
ORCID

Job Title

Doctor

First Name

Betül

Last Name

Bayraktutar

Name

Name Variants

Bayraktutar, Betül

Email Address

Birth Date

Filters

2018 - 201932020 - 20211

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.db2ea70f-7843-435f-a86b-d7652ea75236

Search Results

Now showing 1 - 4 of 4
  • Placeholder
    PublicationMetadata only
    Can rotational thromboelastometry be a new predictive tool for retinal vein occlusion development?
    (Taylor & Francis, 2019) Şahin, Deniz Gören; Özkaya, Abdullah; Bayraktutar, Betül; Taş, Ayşe Yıldız; Akay, Olga Meltem; Yalçın, Özlem; Şahin, Afsun; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; 200905; 170966; 218440; 171267
    Purpose: To evaluate clotting dynamics by a new tool called rotational tromboelastometry (ROTEM) in retinal vein occlusion.Materials and methods: Thirty-six patients who were diagnosed with retinal vein occlusion and 43 age and sex matched healthy controls were included in this study. Diabetes and use of anticoagulant therapy were exclusion criteria. All study participants underwent detailed ophthalmologic and systemic medical examination, including blood pressure measurement, hemoglobin-hematocrit levels, platelet count, coagulation parameters including prothrombin time, activated partial thromboplastin time, fibrinogen levels, and D-dimer levels. Peripheral blood samples were collected and analyzed with ROTEM Coagulation Analyzer (Tem International, Munich, Germany).Results: The RVO patients and controls did not differ with respect to age, sex, hemoglobin, hematocrit, platelet numbers, prothrombin time, activated partial thromboplastin time, fibrinogen levels, D-dimer levels, and glucose levels. When extrinsic thromboelastometry results were analyzed, RVO patients showed a significantly decreased clotting time (76.515.0 vs. 95.0 +/- 21s, respectively; p =0.01) and clot formation time (83.3 +/- 22 vs. 99.7 +/- 24s; p =0.01) as compared with healthy controls. Other ROTEM parameters did now show any difference between two groups.Conclusion: Patients with retinal vein occlusion showed faster clotting time and shorter clotting formation time as compared with healthy controls. ROTEM detects the altered clotting dynamics and may be a useful tool to elucidate the disease pathophysiology. Further studies are needed to investigate if it can be used as a screening test for individuals who are under risk to develop RVO or as a first step test to evaluate hypercoagulable state in RVO.
  • Placeholder
    PublicationMetadata only
    Management and therapy report
    (Medical Network, 2018) N/A; N/A; Şahin, Afsun; Bayraktutar, Betül; Faculty Member; Doctor; School of Medicine; N/A; Koç University Hospital; 171267; N/A
    Dry eye is one of the most common diseases that ophthalmologists face during clinical practice and is characterized by tear hyperosmolarity and ocular surface inflammation. Treatment strategies vary between clinicians and artificial tears are the most commonly used agents, in addition, biologic agents, topical antiinflammatory agents, secretagogues and surgical approches are available. DEWS II report aims to improve homeostasis, break the vicious circle and protect ocular surface comfort. Therefore, stepwise treatment algorithm was recommended in the report based on evoporative/aqueous deficiency dry eye differential diagnosis. Step by step treatment should be planned following detailed history of patient, risk analyses and diagnostic tests. At first step, information about the disease, lifestyle changes and artificial tears, at second step topical antiinflammatory drugs, at third step biological agents and oral sekretagogue and at last step surgical approches are highlighted. It is recommended to skip to upper step if the symptoms and findings of patients do not relieve / Multifaktöryel etyolojiye sahip, gözyaşı hiperosmolaritesi ve oküler yüzey inflamasyonu ile karakterize kuru göz hastalığı, oftalmoloji pratiğinde en sık karşılaşılan hastalık gruplarından biridir. Tedavi yaklaşımı klinisyenler arasında ciddi farklılıklar göstermektedir ve suni gözyaşı preparatları en sık tercih edilen ajanlar olsa da, biyolojik ajanlar, topikal antiinflamatuvar ajanlar, sekretogoglar ve cerrahi tedavi seçenekleri gibi pek çok tedavi ajanı söz konusudur. DEWS II raporunun hedefi; oküler yüzeyde homeostasisi yeniden sağlamak, inflamasyon kısır döngüsünü kırmak ve oküler yüzey konforunun uzun süre korunabilmesidir. Bu amaçla basamaklı tedavi algoritması önerilmiştir ve bunun temelinde evoporatif ve/veya aköz yetmezlik kuru göz ayırıcı tanısı yapılması gerekmektedir. Hasta anamnezi, risk analizi ve tanı testleri derinleştirildikten sonra uygun basamakla tedaviye başlanmalıdır. Birinci basamakta, hastanın bilgilendirilmesi ve yaşam tarzı değişiklikleri, suni gözyaşı desteği, ikinci basamakta topikal antiinflamatuvar tedavi, üçüncü basamakta biyolojik ajanlar ve oral sekretogoglar ve son aşamada ise cerrahi müdahaleler öne çıkmaktadır. Hasta semptom ve bulgularında yeterli iyileşme sağlanamaması durumunda bir üst basamakta yer alan tedavi seçeneklerine geçilmesi önerilmektedir.
  • Placeholder
    PublicationMetadata only
    Novel corneal crosslinking technique with eosin-Y and visible light
    (Wiley, 2019) N/A; N/A; N/A; Department of Chemical and Biological Engineering; Department of Chemical and Biological Engineering; N/A; Yıldız, Erdost; Nazeer, Muhammad Anwaar; Bayraktutar, Betül; Zibandeh, Noushin; Kızılel, Seda; Şahin, Afsun; PhD Student; PhD Student; Doctor; Researcher; Faculty Member; Faculty Member; Department of Chemical and Biological Engineering; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); Graduate School of Health Sciences; Graduate School of Sciences and Engineering; N/A; College of Engineering; School of Medicine; N/A; N/A; Koç University Hospital; N/A; N/A; N/A; N/A; 28376; 171267
    Purpose: Keratoconus is a progressive disease which results thinning of the cornea and increase in the forward curvature of the cornea until corneal rupture. The first choice in clinical management of keratoconus is Ultraviolet-A(UV-A) crosslinking procedure with riboflavin. This procedure is painful, prolonged and has many side effects on the patient. Eosin-y is well known molecule and it has been used as crosslinker with visible light on hydrogels with various cells. Methods: Firstly, we have examined effects of sequential concentrations of eosin-y on proliferation and apoptosis of human corneal epithelial cells (HCECs). We have used MTT cytotoxicity assay, Xcelligence real-time cell analysis, Ki67 and Caspase-3 immunofluorescence staining. After these tests, visible light (525 nm) induced crosslinking has performed with Eosin-Y in fresh bovine corneas at selected doses. Corneas which applied eosin-y or riboflavin, or saline are observed under scanning electron microscopy for topographic, cross-sectional and elemental analysis. Their young moduli measured with hybrid rheometer. Lastly, resistance to osmotic stress and chemical digestion of the corneas compared with water swelling test and enzymatic digestion test, respectively. Results: We have demonstrated non-toxic doses of eosin-y with cytotoxicity and immunofluorescence experiments on HCECs. We determined LD50 concentration of eosin-y for HCECs. After that, we have showed significant crosslinking with eosin-y in fresh bovine corneas. Eosin-y and visible light procedure has created faster and stronger corneal crosslinking reaction on bovine corneas compared to riboflavin and UV-A procedure. Conclusions: We have observed, eosin-y initiate faster and stronger crosslinking in corneal stroma at subtoxic doses than standard procedure. It could be new photo-initiator agent for corneal crosslinking procedure in clinics. For next step, we will examine its toxicity on corneal stromal cells and corneal endothelial cells.
  • Thumbnail Image
    PublicationOpen Access
    A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: in vivo corneal confocal microscopy
    (Sage, 2021) Zimmermann, Hanna; Brandt, Alexander U.; Paul, Friedemann; Altıntaş, Ayşe; Taş, Ayşe Yıldız; Yılmaz, Sezen Güçlü; Bayraktutar, Betül; Cömert, Melis Cansu; Şahin, Afsun; Faculty Member; Faculty Member; Undergraduate Student; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; 11611; N/A; N/A; N/A; N/A; 171267
    Background: neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disorder that damages optic nerves, brainstem, and spinal cord. In vivo corneal confocal microscopy (IVCM) is a noninvasive technique that provides corneal images with dendritic cells (DCs) and corneal subbasal nerve plexus (SBP), which arises from the trigeminal nerve. Objective: we investigated corneal SBP changes in NMOSD and proposed IVCM as a potential new disease severity biomarker for NMOSD. Methods: seventeen age-sex matched NMOSD patients and 19 healthy participants underwent complete neurologic and ophthalmologic examinations. The duration of disease, first symptom, presence of optic neuritis attack, antibody status, Expanded Disability Status Scale(EDSS) score and disease severity score(DSS) were recorded. Retinal nerve fibre layer (RNFL) thickness was measured with optical coherence tomography, and corneal SBP images were taken with IVCM. Results: NMOSD patients had significantly reduced corneal nerve fibre lenght-density and corneal nerve branch lenght-density compared with controls, while DC density was increased. NMOSD patients also showed significantly reduced RNFL thickness compared with controls. EDSS,DSS levels were inversely correlated with IVCM parameters. Conclusion: we observed significant corneal nerve fibre loss in NMOSD patients in relation to disease severity. IVCM can be a candidate noninvasive imaging method for axonal damage assessment in NMOSD that warrants further investigation.